特此公告。 证券代码：300003 证券简称：乐普医疗 公告编号：2025-065 乐普（北京）医疗器械股份有限公司 关于归还用于暂时补充流动资金的闲置募集资金公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 乐普（北京）医疗器械股份有限公司（以下简称：公司）于2024年8月23 日召开第六届董事会第九次会议和第六届监事会第七次会议，审议通过了《关于 使用部分闲置募集资金暂时补充流动资金》的议案，同意公司在保证募集资金投 资项目资金使用的前提下，使用闲置募集资金不超过人民币60,000万元用于暂时 补充流动资金，使用期限自董事会审议通过之日起不超过12个月，到期归还至 募集资金专用账户，具体内容详见公司于2024年8月24日在巨潮资讯网披露的 《关于使用部分闲置募集资金暂时补充流动资金的公告》（公告编号：2024-088）。 2025年8月20日，公司已将用于暂时补充流动资金的闲置募集资金60,000万 元归还至公司募集资金专用账户，使用期限未超过12个月，公司已将上述募集 资金的归还情况通知了公司保荐机构。 乐普（北京）医疗器械股份有限公司 董事会 二○ ...

证券代码：300003 证券简称：乐普医疗 公告编号：2025-064 | | | 是否为控股 | | 占其所 | 占公司 | 是 否 | 为 | 是否为 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 质权人 | 股东 名称 | 股东或第一 大股东及其 | 本次质押数 量（股） | 持股份 | 总股本 | 限售股 | | 补充质 | 质押起始日 | 质押到期日 | | 质押用途 | | | | 一致行动人 | | 比例 | 比例 | | | 押 | | | | | | 中国银河 | 蒲忠杰 | 是 | 32,000,000 | 7.02% | 1.70% | 高管锁 定股 | | 否 | 2025 年 8 月 19 日 | 无固定期限 | 证券股份 有限公司 | 偿还债务 | 1 三、股份累计质押情况 乐普（北京）医疗器械股份有限公司 关于控股股东部分股权质押及解除质押的公告 公司控股股东蒲忠杰先生及其一致行动人保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误 ...

Group 1 - The A-share market showed mixed results, with the medical device ETF fund (159797) rising nearly 1%, marking a strong push for five consecutive days of gains [1] - The medical device ETF fund (159797) received a net subscription of 12 million units during the day, achieving a net inflow for 12 consecutive days, totaling over 130 million yuan [1] - Major stocks within the medical device ETF fund saw significant gains, including Mindray Medical up 4.35% and Hotgen Biotech up 6% [2][5] Group 2 - Recent high-level research in Beijing emphasized the need for increased high-quality technological supply and policy support in the biopharmaceutical industry, aiming to enhance the quality and efficiency of drug development [2] - The total bid amount for medical devices in July reached 12.643 billion yuan, a year-on-year increase of 20%, with a total of 96.785 billion yuan for the first seven months, reflecting a 57% year-on-year growth [3] Group 3 - The brain-computer interface industry is expected to accelerate due to supportive policies, with a target for key technological breakthroughs by 2027 [4] - The global market for brain-computer interfaces in medical applications is projected to reach 40 billion USD by 2030 and exceed 145 billion USD by 2040 [6] Group 4 - The medical device ETF fund (159797) covers core areas of medical devices, including high-value consumables and in vitro diagnostics, with the top ten weighted stocks accounting for over 44% of the fund [7]

Group 1 - The medical device sector is experiencing a strong performance, with the CSI All Medical Device Index rising by 1.41% as of August 21, 2025, and notable stocks such as Meihua Medical increasing by 14.12% [1] - The Medical Device ETF (159797) has shown a consistent upward trend, achieving a 1.55% increase over the past week and a 1.17% rise on the day of reporting [1] - The Medical Device ETF has seen significant liquidity, with a turnover rate of 7.13% and nearly 20 million yuan in trading volume [1] Group 2 - The Medical Device ETF has reached a new high in scale at 255 million yuan and a new high in shares at 300 million, indicating strong investor interest [2] - Over the past 11 days, the ETF has experienced continuous net inflows, totaling 122 million yuan, with a peak single-day inflow of 31.28 million yuan [2] Group 3 - Recent government initiatives emphasize the importance of high-quality technological supply and policy support for the biopharmaceutical industry, aiming to enhance the quality and efficiency of medical products [5] - The total bid amount for medical devices in July reached 12.643 billion yuan, reflecting a year-on-year growth of 20%, with a total of 96.785 billion yuan for the first seven months, marking a 57% increase [5] - The Ministry of Industry and Information Technology has issued guidelines to promote the innovation of brain-computer interface technology, aiming for breakthroughs by 2027 [5] Group 4 - The brain-computer interface industry is expected to see significant growth driven by technological innovation, policy support, and capital investment, particularly in healthcare and consumer markets [6] - The Medical Device ETF encompasses a wide range of sectors, including high-value consumables and in-vitro diagnostics, with the top ten weighted stocks accounting for over 44% of the fund [6]

Core Viewpoint - Lepu Medical's stock closed at 18.07 yuan, down 2.27%, with a rolling PE ratio of 236.64 times, significantly higher than the industry average of 59.49 times [1] Company Summary - Lepu Medical's main business includes medical devices, pharmaceuticals, medical services, and health management [1] - The latest quarterly report for Q1 2025 shows revenue of 1.736 billion yuan, a year-on-year decrease of 9.67%, and a net profit of 379 million yuan, down 21.44%, with a gross profit margin of 64.03% [1] Shareholder Information - As of March 31, 2025, Lepu Medical had 94,228 shareholders, an increase of 583 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Summary - The average PE ratio for the medical device industry is 59.49 times, with a median of 40.19 times, placing Lepu Medical at the 115th position in the industry ranking [2]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗器械板块主力资金净流出6.22亿元，游资资金净流入8454.45万元，散户资 金净流入5.38亿元。医疗器械板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300049 | 福瑞股份 | 1.46 Z | 11.88% | -1.05 Z | -8.52% | -4138.97万 | -3.36% | | 300003 | 乐普医疗 | 1.21 Z | 7.97% | -5108.00万 | -3.37% | -6962.47万 | -4.59% | | 600645 | 中源协和 | 9348.49万 | 9.75% | -3949.64万 | -4.12% | -5398.85万 | -5.63% | | 688271 | 联影医疗 | ...

Group 1 - The core point of the article is that the FDA has accelerated the approval of Wegovy (2.4 mg semaglutide) for treating moderate to severe liver fibrosis in adult patients with non-alcoholic steatohepatitis (NASH), leading to significant stock price increases for several pharmaceutical companies [1] Group 2 - Hanyu Pharmaceutical's stock rose over 10% following the news [1] - Companies such as Sunlight Novo and Jinkai Biotechnology saw stock increases of over 5% [1] - Novo Nordisk's stock rose over 6% in after-hours trading in the US market due to the FDA announcement [1]

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown significant growth, indicating a positive trend in the healthcare sector [1]. Group 1: Index Performance - The CSI Healthcare Equipment and Services Index increased by 1.49%, reaching 15,129.06 points, with a trading volume of 32.457 billion [1]. - Over the past month, the index has risen by 9.35%, by 9.86% over the last three months, and by 8.89% year-to-date [1]. Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, reflecting the overall performance of these companies [1]. - The top ten weighted companies in the index include Mindray Medical (9.08%), United Imaging (7.41%), Aier Eye Hospital (7.13%), and others [1]. - The index's holdings are primarily from the Shenzhen Stock Exchange (59.69%) and the Shanghai Stock Exchange (40.31%) [1]. Group 3: Industry Representation - The index exclusively represents the pharmaceutical and healthcare industry, with a 100% allocation to this sector [1]. Group 4: Index Adjustment and Fund Tracking - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2]. - Public funds tracking the healthcare index include various Southern and Tianhong funds, as well as ETFs from multiple asset management companies [2].

Core Viewpoint - The article highlights the emergence of a new model in elderly care services, exemplified by the "Elderly Care Home" in Beijing, which aims to provide comprehensive, inclusive, and professional care services for the elderly in the community [1][3]. Group 1: Facility Overview - The "Elderly Care Home" is set to open in November 2024, featuring six floors with 125 furnished rooms and 300 beds, offering various functional areas including an elderly university, care services, community dining, and health service stations [3]. - The facility includes specialized areas for dementia and disability care, with a community dining area already designated as "Haidian Dining Hall" [3]. Group 2: Service Model - The care home operates on a model that combines government subsidies with self-payment from the elderly, aiming to provide sustainable care support [3]. - The "1+3+N" service model is being developed, which includes "1 platform," "3 major scenarios," and "N services," focusing on integrated smart elderly care services [3][8]. Group 3: Strategic Goals - The care home aims to serve not only institutional and community needs but also to extend services to families, emphasizing education and training for caregivers to enhance their skills in using smart technologies [4][12]. - The goal is to reach 10,000 families within a 10-kilometer radius, integrating various types of elderly care services into a standardized and replicable system [4][12]. Group 4: Technology Integration - A smart elderly care platform will be established, utilizing SaaS technology and connected health monitoring devices to provide personalized services based on individual needs [8][10]. - The integration of smart technology is expected to improve service efficiency and quality, allowing caregivers to monitor and respond to the needs of the elderly more effectively [10][13]. Group 5: Industry Trends - The article notes a trend towards smaller, personalized service providers in the elderly care sector, which will complement larger service groups by offering more flexible and individualized care [14]. - The industry faces challenges such as the need for product innovation and the integration of services, emphasizing the importance of "product as service" in meeting the needs of the elderly [15][16].

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Lepu Medical, indicating a significant decline in revenue and profit in the latest quarterly report [1][2] - As of August 14, Lepu Medical's stock closed at 17.1 yuan, down 4.63%, with a rolling price-to-earnings (PE) ratio of 223.93 times, significantly higher than the industry average of 55.76 times [1][2] - The company's total market capitalization is 32.158 billion yuan, ranking it 116th in the medical device industry based on PE ratio [1][2] Group 2 - For the first quarter of 2025, Lepu Medical reported a revenue of 1.736 billion yuan, a year-on-year decrease of 9.67%, and a net profit of 379 million yuan, down 21.44% year-on-year, with a gross profit margin of 64.03% [1] - The average PE ratio for the medical device industry is 55.76, with a median of 39.14, indicating that Lepu Medical's valuation is significantly above its peers [2] - As of March 31, 2025, Lepu Medical had 94,228 shareholders, an increase of 583 from the previous count, with an average holding value of 352,800 yuan per shareholder [1]